Devyser Diagnostics AB publishes quarterly report for July to September 2023
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further...
News | May 23, 2023
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma samples. Due to the very low concentrations of cfDNA found in plasma, robust pre-analytical methods are needed to enable sensitive detection in downstream applications and reliable results.
Devyser and QIAGEN are collaborating to evaluate automated bead-based purification of cfDNA from plasma samples on the QIAsymphony SP instrument for non-invasive fetal RHD detection.
We determined that using the QIAGEN dedicated kit for cfDNA extraction and the Devyser RHD qPCR assay successfully allowed RHD determination from 1ml plasma.
Results from the joint study will be presented at the 5th International Meeting on Cell-Free DNA in Copenhagen, May 25 – 26 2023.
